Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) on February 27, 2017, reporting an event that occurred on February 21, 2017. The company develops the Argus II Retinal Prosthesis, a medical device indicated for blind individuals suffering from advanced outer retinal degenerative diseases such as retinitis pigmentosa (RP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical milestone and does not contain financial statements or quantitative financial data.
Material Changes
The material event reported is the completion of the 30th implant of the Argus II Retinal Prosthesis by Professor Stanislao Rizzo. This surgery was performed on February 9, 2017, at the Azienda Ospedaliero Universitaria Careggi in Florence, Italy. This milestone contributes to the total of more than 220 Argus II implants performed worldwide.
Outlook, Risks, and Management Commentary
Management highlighted the expansion of the Argus II's presence in Europe, noting that Professor Rizzo has been implanting the system in Italy since 2011 and has trained surgeons at several international centers. The filing notes that retinitis pigmentosa affects an estimated 167,000 Europeans. No specific financial guidance, risks, or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the total number of Argus II implants worldwide (stated as more than 220).
- Confirm the regulatory status and reimbursement landscape for Argus II in Italy and the broader European market.
- Review the company's most recent 10-K or 10-Q for actual financial performance, as this 8-K contains no financial data.
- Assess the commercialization strategy for the Argus II in Europe given the specific disease prevalence cited.